Search Results - "ORLOFF, John J"

Innovative approaches to clinical development and trial design by Orloff, John J, Stanski, Donald

“…Pharmaceutical innovation is increasingly risky, costly and at times inefficient, which has led to a decline in industry productivity. Despite the increased…”
Get full text

Zoledronic Acid and Clinical Fractures and Mortality after Hip Fracture by Lyles, Kenneth W, Colón-Emeric, Cathleen S, Magaziner, Jay S, Adachi, Jonathan D, Pieper, Carl F, Mautalen, Carlos, Hyldstrup, Lars, Recknor, Chris, Nordsletten, Lars, Moore, Kathy A, Lavecchia, Catherine, Zhang, Jie, Mesenbrink, Peter, Hodgson, Patricia K, Abrams, Ken, Orloff, John J, Horowitz, Zebulun, Eriksen, Erik Fink, Boonen, Steven

“…Mortality is increased in the year after a hip fracture, and strategies that improve the outcome are needed. This randomized, double-blind, placebo-controlled…”
Get full text

Communicating With the FDA: The "Third Rail" of a New Model for Drug Development by Stanski, Donald R., Orloff, John J.

Get full text

Prevention of acute ischemic renal failure by targeted delivery of growth factors to the proximal tubule in transgenic mice: the efficacy of parathyroid hormone-related protein and hepatocyte growth factor by FIASCHI-TAESCH, Nathalie M, SANTOS, Soledad, REDDY, Vasumathi, VAN WHY, Scott K, PHILBRICK, William F, ORTEGA, Arantxa, ESBRIT, Pedro, ORLOFF, John J, GARCIA-OCANA, Adolfo

“…Treatment of acute renal failure (ARF) would be enhanced by identification of factors that accelerate renal recovery from injury. Parathyroid hormone-related…”
Get full text

Therapeutic equivalence of alendronate 35 milligrams once weekly and 5 milligrams daily in the prevention of postmenopausal osteoporosis by Luckey, Marjorie M, Gilchrist, Nigel, Bone, Henry G, Davie, Michael W, de Villiers, Tobias J, Wu, Mei, Daifotis, Anastasia G, Santora, Arthur C, Orloff, John J

“…To evaluate the efficacy and safety of alendronate 35 mg once weekly compared with alendronate 5 mg daily in the prevention of osteoporosis. We compared the…”
Get full text

Immunochemical Characterization of Circulating Parathyroid Hormone–Related Protein in Patients with Humoral Hypercalcemia of Cancer by Burtis, William J, Brady, Thomas G, Orloff, John J, Ersbak, Julie B, Warrell, Raymond P, Olson, Beatriz R, Wu, Terence L, Mitnick, MaryAnn E, Broadus, Arthur E, Stewart, Andrew F

“…Tumors from patients with humoral hypercalcemia of cancer produce a parathyroid Hormone-Related protein (PTHRP). We have developed two region-specific…”
Get full text

Stromal Cells Are Critical Targets in the Regulation of Mammary Ductal Morphogenesis by Parathyroid Hormone-Related Protein by Dunbar, Maureen E., Young, Peter, Zhang, Jian-Ping, McCaughern-Carucci, James, Lanske, Beate, Orloff, John J., Karaplis, Andrew, Cunha, Gerald, Wysolmerski, John J.

“…Parathyroid hormone-related protein (PTHrP) was originally identified as the tumor product responsible for humoral hypercalcemia of malignancy. It is now known…”
Get full text

Recommendations for the Registration of Agents to be Used in the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis: Updated Recommendations from the Group for the Respect of Ethics and Excellence in Science by Abadie, Eric C., Devogealer, Jean-Pierre, Ringe, Johann D., Ethgen, Dominique J., Bouvenot, Gilles M., Kreutz, Gottfried, Laslop, Andrea, Orloff, John J., Vanderauwera, Philippe M., Delmas, Pierre D., Dere, Willard H., Branco, Jaime, Altman, Roy D., Avouac, Bernard P., Menkes, Charles J., Vanhaelst, Luc, Mitlak, Bruce H., Tsouderos, Yannis, Reginster, Jean-Yves L.

“…The Group for the Respect and Excellence in Science (GREES) has reviewed and updated their recommendations for clinical trials to evaluate the efficacy and…”
Get full text

Parathyroid hormone-like proteins: biochemical responses and receptor interactions by Orloff, J J, Wu, T L, Stewart, A F

Get more information

Immunohistochemical detection of parathyroid hormone-related protein in a cutaneous squamous cell carcinoma causing humoral hypercalcemia of malignancy by Crespo, M, Sopeña, B, Orloff, J J, Cameselle Teijeiro, J F, Dann, P, Andrade, M A, Freire, M, de la Fuente, J, Martinez-Vazquez, C

“…Humoral hypercalcemia of malignancy is a cancer-related hypercalcemia caused by production of humoral factors by malignant cells in patients without bone…”
Get full text

Evaluation of housestaff physicians’ preparation and interpretation of sputum gram stains for communityacquired pneumonia by Fine, Michael J., Orloff, John J., Rihs, John D., Vickers, Richard M., Kominos, Spyros, Kapoor, Wishwa N., Arena, Vincent C., Yu, Victor L.

Get full text

Innovative approaches to clinical development and trial design: New challenges in translational medicine: transforming the advancement of science into cures by ORLOFF, John J, STANSKI, Donald

Get full text

Interspecies comparison of renal cortical receptors for parathyroid hormone and parathyroid hormone‐related protein by Orloff, John J., Goumas, Douglas, Wu, Terence L., Stewart, Andrew F.

“…Parathyroid hormone (PTH) and PTH‐related proteins (PTHrP) interact with a common receptor in rat bone cells and in canine renal membranes with similar…”
Get full text

Zoledronic Acid in Reducing Clinical Fracture and Mortality after Hip Fracture by Lyles, Kenneth W., Colón-Emeric, Cathleen S., Magaziner, Jay S., Adachi, Jonathan D., Pieper, Carl F., Mautalen, Carlos, Hyldstrup, Lars, Recknor, Chris, Nordsletten, Lars, Moore, Kathy A., Lavecchia, Catherine, Zhang, Jie, Mesenbrink, Peter, Hodgson, Patricia K., Abrams, Ken, Orloff, John J., Horowitz, Zebulun, Eriksen, Erik Fink, Boonen, Steven

Get full text

Further evidence for a novel receptor for amino-terminal parathyroid hormone-related protein on keratinocytes and squamous carcinoma cell lines by Orloff, J J, Kats, Y, Urena, P, Schipani, E, Vasavada, R C, Philbrick, W M, Behal, A, Abou-Samra, A B, Segre, G V, Jüppner, H

“…PTH and PTH-related peptides (PTHrPs) interact with a common PTH/PTHrP receptor (type I), which is expressed in many tissues, including bone and kidney…”
Get more information

Therapeutic Equivalence of Alendronate 35 Milligrams Once Weekly and 5 Milligrams Daily in the Prevention of Postmenopausal Osteoporosis by Luckey, Marjorie M., Gilchrist, Nigel, Bone, Henry G., Davie, Michael W., de Villiers, Tobias J., Wu, Mei, Daifotis, Anastasia G., Santora, Arthur C., Orloff, John J.

Get full text

A midregion parathyroid hormone-related peptide mobilizes cytosolic calcium and stimulates formation of inositol trisphosphate in a squamous carcinoma cell line by Orloff, J J, Ganz, M B, Nathanson, M H, Moyer, M S, Kats, Y, Mitnick, M, Behal, A, Gasalla-Herraiz, J, Isales, C M

“…A midregion fragment of PTH-related protein (PTHrP), which is intensively conserved across species, has been identified as a secretory product of several…”
Get full text

Recommendations for the registration of agents to be used in the prevention and treatment of glucocorticoid-lnduced osteoporosis: Updated recommendations from the Group for the Respect of Ethics and Excellence in Science by ABADIE, Eric C, DEVOGEALER, Jean-Pierre, DERE, Willard H, BRANCO, Jaime, ALTMAN, Roy D, AVOUAC, Bernard P, MENKES, Charles J, VANHAELST, Luc, MITLAK, Bruce H, TSOUDEROS, Yannis, REGINSTER, Jean-Yves L, RINGE, Johann D, ETHGEN, Dominique J, BOUVENOT, Gilles M, KREUTZ, Gottfried, LASLOP, Andrea, ORLOFF, John J, VANDERAUWERA, Philippe M, DELMAS, Pierre D

Get full text

The carboxy-terminus of parathyroid hormone--inert or invaluable? by Orloff, J J, Stewart, A F

Get more information

Expression and role of parathyroid hormone-related protein in human renal proximal tubule cells during recovery from ATP depletion by GARCIA-OCANA, A, GALBRAITH, S. C, VAN WHY, S. K, KAI YANG, GOLOVYAN, L, DANN, P, ZAGER, R. A, STEWART, A. F, SIEGEL, N. J, ORLOFF, J. J

“…Parathyroid hormone (PTH)-related protein (PTHrP) is widely expressed in normal fetal and adult tissues and regulates growth and differentiation in a number of…”
Get full text